GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Net Margin %

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Net Margin % : -241,760.00% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Freeline Therapeutics Holdings's Net Income for the three months ended in Sep. 2023 was $-12.09 Mil. Freeline Therapeutics Holdings's Revenue for the three months ended in Sep. 2023 was $0.01 Mil. Therefore, Freeline Therapeutics Holdings's net margin for the quarter that ended in Sep. 2023 was -241,760.00%.

The historical rank and industry rank for Freeline Therapeutics Holdings's Net Margin % or its related term are showing as below:

FRLN' s Net Margin % Range Over the Past 10 Years
Min: -8140.42   Med: 0   Max: 0
Current: -8140.42


FRLN's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -148.41 vs FRLN: -8140.42

Freeline Therapeutics Holdings Net Margin % Historical Data

The historical data trend for Freeline Therapeutics Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Net Margin % Chart

Freeline Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Net Margin %
- - - - -

Freeline Therapeutics Holdings Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -2,594.98 -241,760.00

Competitive Comparison of Freeline Therapeutics Holdings's Net Margin %

For the Biotechnology subindustry, Freeline Therapeutics Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Freeline Therapeutics Holdings's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's Net Margin % falls into.



Freeline Therapeutics Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Freeline Therapeutics Holdings's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-88.972/0
= %

Freeline Therapeutics Holdings's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin=Net Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-12.088/0.005
=-241,760.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Freeline Therapeutics Holdings  (NAS:FRLN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Freeline Therapeutics Holdings Net Margin % Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Headlines